Literature DB >> 19502186

Managing toxicities associated with colorectal cancer chemotherapy and targeted therapy: a new guide for nurses.

Nina N Grenon1, Jennifer Chan.   

Abstract

This article will provide an overview of the principal toxicities associated with commonly used chemotherapy treatment regimens for metastatic colorectal cancer (mCRC) and explore the role of the oncology nurse in the management of treatment-associated toxicity. Although patients with mCRC have benefited considerably from recent therapeutic advances, the use of more complex treatment regimens has inevitably resulted in an increase in treatment-related toxicities. This can ultimately lead to dose reductions, delays, or discontinuation of therapy, which may negatively affect efficacy outcomes. Early identification and treatment of toxicities often can allow treatment to continue as planned or at a lower dose, if required. The oncology nurse is ideally positioned to assist with the timely recognition and management of side effects. This allows therapy to be continued on schedule and at the appropriate dose, enabling patients to achieve a better clinical outcome and maintain or improve their quality of life.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19502186     DOI: 10.1188/09.CJON.285-296

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  11 in total

1.  Changes in fatigue in rectal cancer patients before and after therapy: a systematic review and meta-analysis.

Authors:  Chang Wen-Pei; Jen Hsiu-Ju
Journal:  Support Care Cancer       Date:  2020-01-30       Impact factor: 3.603

2.  Symptom prevalence, frequency, severity, and distress during chemotherapy for patients with colorectal cancer.

Authors:  Gunilla Pettersson; Carina Berterö; Mitra Unosson; Sussanne Börjeson
Journal:  Support Care Cancer       Date:  2013-12-13       Impact factor: 3.603

3.  Engineering bacteria for cancer therapy.

Authors:  Tetsuhiro Harimoto; Tal Danino
Journal:  Emerg Top Life Sci       Date:  2019-11-11

4.  Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study.

Authors:  E Gustafsson; E Litström; C Berterö; J Drott
Journal:  Support Care Cancer       Date:  2015-07-04       Impact factor: 3.603

5.  Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer.

Authors:  Penelope E Schofield; M R Stockler; D Zannino; N C Tebbutt; T J Price; R J Simes; N Wong; N Pavlakis; D Ransom; E Moylan; C Underhill; D Wyld; I Burns; R Ward; N Wilcken; M Jefford
Journal:  Support Care Cancer       Date:  2015-06-21       Impact factor: 3.603

6.  Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.

Authors:  Josef Thaler; Meinolf Karthaus; Laurent Mineur; Richard Greil; Henry Letocha; Ralf Hofheinz; Eva Fernebro; Erick Gamelin; Ana Baños; Claus-Henning Köhne
Journal:  BMC Cancer       Date:  2012-09-29       Impact factor: 4.430

7.  Common Symptoms and Distress Experienced Among Patients with Colorectal Cancer: A Qualitative part of Mixed Method Design.

Authors:  Sussanne Börjeson; Hans Starkhammar; Mitra Unosson; Carina Berterö
Journal:  Open Nurs J       Date:  2012-09-06

8.  Antitumor effect of D-erythrose in an abdominal metastatic model of colon carcinoma.

Authors:  Li-Li Liu; Tao Yi; Xia Zhao
Journal:  Oncol Lett       Date:  2014-12-03       Impact factor: 2.967

9.  Neoadjuvant short-course radiotherapy with consolidation chemotherapy for locally advanced rectal cancer: a systematic review and meta-analysis.

Authors:  Agastya Patel; Piotr Spychalski; Giulia Corrao; Barbara A Jereczek-Fossa; Robert Glynne-Jones; Julio Garcia-Aguilar; Jarek Kobiela
Journal:  Acta Oncol       Date:  2021-07-24       Impact factor: 4.311

10.  Experiences With a Self-Reported Mobile Phone-Based System Among Patients With Colorectal Cancer: A Qualitative Study.

Authors:  Jenny Drott; Maria Vilhelmsson; Karin Kjellgren; Carina Berterö
Journal:  JMIR Mhealth Uhealth       Date:  2016-06-09       Impact factor: 4.773

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.